Nicox 
Welcome,         Profile    Billing    Logout  
 9 Products   21 Diseases  9 Products   2 Trials   541 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cerdulatinib (ALXN2075) / Nicox, AstraZeneca
NCT04757259: Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

No Longer Available
N/A
NA
cerdulatinib, PRT062070
Alexion Pharmaceuticals, Inc.
Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma
 
 
Vyzulta (latanoprostene bunod) / Bausch Health, Nicox
NCT04140279: A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Withdrawn
4
34
US
Latanoprostene Bunod, Vyzulta®, Placebo, Bausch + Lomb ReNu MultiPlus® Lubricating and Rewetting Drops
Bausch & Lomb Incorporated
Ocular Hypertension
08/23
08/23
Zerviate (cetirizine ophthalmic solution) / Nicox, Santen
NCT04319757: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Completed
1
12
US, RoW
ACE1702, Cyclophosphamide, Fludarabine
Acepodia Biotech, Inc.
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
07/24
07/24
bimatoprost grenod (NCX 470) / Nicox
Denali, NCT04630808: MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
696
US, RoW
NCX 470 0.1%, NCX 470, Latanoprost 0.005%, Latanoprost
Nicox Ophthalmics, Inc.
Open Angle Glaucoma, Ocular Hypertension
04/25
07/25
Whistler, NCT05938699: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

Completed
2/3
18
US
NCX 470, nitric oxide (NO)-donating bimatoprost prostaglandin analog, Placebo, Artificial tears
Nicox Ophthalmics, Inc.
Open Angle Glaucoma
03/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cerdulatinib (ALXN2075) / Nicox, AstraZeneca
NCT04757259: Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

No Longer Available
N/A
NA
cerdulatinib, PRT062070
Alexion Pharmaceuticals, Inc.
Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma
 
 
Vyzulta (latanoprostene bunod) / Bausch Health, Nicox
NCT04140279: A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Withdrawn
4
34
US
Latanoprostene Bunod, Vyzulta®, Placebo, Bausch + Lomb ReNu MultiPlus® Lubricating and Rewetting Drops
Bausch & Lomb Incorporated
Ocular Hypertension
08/23
08/23
Zerviate (cetirizine ophthalmic solution) / Nicox, Santen
NCT04319757: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Completed
1
12
US, RoW
ACE1702, Cyclophosphamide, Fludarabine
Acepodia Biotech, Inc.
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
07/24
07/24
bimatoprost grenod (NCX 470) / Nicox
Denali, NCT04630808: MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
696
US, RoW
NCX 470 0.1%, NCX 470, Latanoprost 0.005%, Latanoprost
Nicox Ophthalmics, Inc.
Open Angle Glaucoma, Ocular Hypertension
04/25
07/25
Whistler, NCT05938699: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

Completed
2/3
18
US
NCX 470, nitric oxide (NO)-donating bimatoprost prostaglandin analog, Placebo, Artificial tears
Nicox Ophthalmics, Inc.
Open Angle Glaucoma
03/25
03/25

Download Options